Calcineurin inhibitors in systemic sclerosis – a systematic literature review

Nina N. Hofmann*, Robert A. Ambühl*, Suzana Jordan and Oliver Distler

Abstract
Objective: To review treatment effectiveness and adverse events of calcineurin inhibitors (CNIs) such as cyclosporin A (CsA) and tacrolimus in patients with systemic sclerosis (SSc).
Methods: A systematic literature search was performed on PubMed and Web of Science using the predefined keywords ‘systemic sclerosis’, scleroderma, cyclosporin*, and tacrolimus. Articles were eligible for inclusion, if SSc patients had been treated with CNIs and data on treatment effects were available.
Results: This systematic literature review identified 37 papers (19 case reports, 15 case series, 2 controlled studies, and 1 retrospective study) including 134 SSc patients treated with CNIs. In 34 of 37 papers, CsA was used. An improvement of skin fibrosis was observed in 77 of 96 (80.2%) patients using a wide variety of outcome measures and dose regimes. Both controlled studies showed significant improvements, one using a historical control group and one using a no-treatment control group. Improvement in pulmonary function tests (PFTs) occurred in 67.9% (19/28) of the patients who had reduced PFTs at baseline. In 58 (43.3%) cases, adverse renal events were reported, of which 7 (5.2%) were severe such as scleroderma renal crisis (SRC), CsA-associated nephropathy, or death by renal insufficiency. Adverse events led to dose reduction, treatment interruption, or withdrawal in 39 of 134 (29.1%).
Conclusion: In this systematic literature review, signals for potential effectiveness of CsA for skin and pulmonary fibrosis were found, but the evidence level of the identified studies was too low to allow robust conclusions. Randomized controlled double-blind trials are needed to conclude on the effectiveness of CNIs in SSc. Renal toxicity of CNIs was confirmed in this review and needs to be considered in the design of such studies.

Keywords: calcineurin inhibitors, cyclosporin A, systemic sclerosis

Introduction
Systemic sclerosis (SSc) is a rare, potentially lethal autoimmune connective tissue disease, characterized by fibrosis affecting the skin and a variety of internal organs.1 Very early disease manifestations are Raynaud’s phenomenon (RP), SSc-specific autoantibodies, and characteristic microvascular changes detected by nailfold capillaroscopy.2 During the course of the disease, the majority of SSc patients develop skin fibrosis, measured by the modified Rodnan skin score (mRSS). Skin thickening is one of the major aspects of the classification criteria for SSc.3,4 Improvement in skin thickness correlates with better functional outcome and lower morbidity and mortality.5,6 Interstitial lung disease (ILD) is detectable in >50% of dcSSc patients and in >30% of lcSSc patients, respectively.7 ILD and pulmonary hypertension (PAH) are the leading causes of SSc-associated deaths.3,6

In the past, the major organ complication was scleroderma renal crisis (SRC), associated with accelerated arterial hypertension and rapidly progressive deterioration of kidney function.9 Nowadays, most likely due to the treatment...
with angiotensin converting enzyme (ACE) inhibitors, it is no longer the leading cause of death. Nevertheless, up to two thirds of cases require long-term dialysis and mortality remains high. To improve poor prognosis, early detection and immediate therapy are important.

Treatment of SSc is challenging, due to the complexity and wide spectrum of disease manifestations. Today, treatment mostly consists of organ-specific management. The updated EULAR recommendations of 2017 and more recent organ-specific management guidelines provide an evidence-based overview concerning pharmacological treatment of SSc-related organ involvement. Symptomatic treatment led to improved clinical outcome over the years. However, established treatments for the overall disease process and fibrotic manifestations are still not available. Autologous hematopoietic stem cell transplantation (HSCT) showed promising results in several randomized controlled clinical trials, but its use might be limited due to increased mortality in the first year of treatment. Recently, based on the findings of the SENSCIS trial, nintedanib was approved for treatment of SSc-ILD in various countries. Nintedanib is a tyrosine kinase inhibitor leading to anti-fibrotic but also to anti-inflammatory effects. Moreover, the FDA approved the interleukin-6 receptor antibody tocilizumab for the treatment of SSc-ILD based on the focuSSced trial.

Cyclosporin A (CsA) and tacrolimus (Tac), a group of immunosuppressive agents referred to as calcineurin inhibitors (CNIs), could be another treatment option for SSc patients. By forming a complex with either cyclophilin or FK506 binding protein (FKBP), they competitively bind to calcineurin, inhibiting translocation of the nuclear (transcription) factor of activated T-cells (NFAT). This leads to a reduced transcription of cytokines and inhibition of T cell activation. Accordingly, CsA has been used to treat patients with SSc and reports with promising effects on skin fibrosis have been published. However, its use in clinical practice and its formal testing in large prospective randomized controlled clinical trials have been restricted by its potential renal toxicity and reports about the occurrence of SRC in patients treated with CsA. Therefore, the aim of this study was to provide a structured and unbiased review of potential effectiveness and toxicity of CNIs in SSc using a systematic literature analysis.

Materials and methods

Systematic literature search
A systematic literature search on PubMed and Web of Science was performed using the following two terms: (1) «systemic sclerosis» OR scleroderma and (2) cyclosporine* OR tacrolimus. Using the advanced search method, one query was added to the other by the word «AND». Filters were applied for language (English, German) and article type (case reports, clinical study, clinical trial, controlled clinical trial, historical article, randomized controlled trial, journal articles). All articles were included up to 31.12.2019. PRISMA guidelines were followed (the PRISMA Checklist is available as supplemental material). The searches were performed by two authors each and uncertainties were discussed.

Inclusion criteria
In addition to the applied filters, preclinical experimental studies, abstracts, letters or congress reports were excluded. Reviews addressing SSc and CNIs were used to screen for additional primary research publications, but not for the primary analysis. Only papers with SSc patients treated with CNIs and available information on the outcome of CNI therapy on SSc disease manifestation were analysed. Therefore, studies of SSc patients receiving CNI therapy for reasons other than SSc (e.g. organ transplantation) were excluded if the effect on SSc was not specified. If this was the case, or if the article did not show the effects of CNI therapy in SSc patients, the reason for exclusion was labelled as ‘No specific analysis for SSc or CNIs’. In addition, articles were excluded, if they reported on other forms of scleroderma (e.g. morphea/ localized scleroderma). Inclusion and exclusion criteria were analysed by the investigators (NH, RAA, SJ, OD) independently. In case of uncertainties and discrepancies, consensus was obtained after discussion.

Data extraction and analysis
Patient characteristics and treatment data of the included articles were collected, including gender, age, subtype, disease duration, disease manifestations, previous treatments, co-treatments, dosage and duration of CNI therapy as well as adverse events. Studies with co-treatment with other immunosuppressive agents including prednisolone (PSL) equivalents >10 mg/d were also listed and analysed separately.
When assessing disease manifestations, many different methods and scores were used for measurement (Table 2).

Different duration of treatments were reported. The most frequent definition was the time from initiation of therapy to the end of follow-up or discontinuation of CNI. If treatment was discontinued and re-administered, treatment periods were added. Time between dose reduction and complete stop of treatment was not included into calculation of therapy duration. In some studies, there was no clear information on therapy duration provided.

Because most of the identified articles were dealing with skin and lung fibrosis, we focused our effectiveness analysis on these two organ manifestations. Accordingly, all available baseline and follow-up measures for skin and lung fibrosis were extracted, and effectiveness as well as side effects of CNI treatment was collected.

Results of the systematic literature search
From the systematic literature search, 249 articles were retrieved, from which 186 were excluded. Reasons for exclusion are listed in Figure 1. References of the remaining 63 papers were screened for additional articles, and one further article was found.24 Finally, 27 review articles were excluded, and the remaining 37 identified primary research articles were included into the analysis.24–60 The 37 articles consisted of 19 case reports, 15 case series, 1 open-label, randomized controlled trial with a no-treatment arm (group I iloprost vs group II iloprost with low-dose CsA), one open-label, prospective study with a historical control group (CSA group vs historical placebo group of the chlorambucil trial),61 and one retrospective study without control (patients received prednisolone (0.5 mg/kg/d) and tacrolimus; Table 1).

Baseline patient characteristics
The 37 studies involved 134 SSc patients treated with CNIs. Patient baseline characteristics are summarized in Table 2. In 15 studies, the classification of SSc was made in accordance to the ACR criteria. Regarding subtype of the disease, 71 patients had dcSSc (53%), 23 lcSSc (17.2%), of which four were diagnosed as having the so-called CREST syndrome (calcinosis, RP, esophageal dysmotility, sclerodactyly, and telangiectasia), and three had overlap SSc (2.2%). Thirty-seven patients (27.6%) had no subtype specified. Out of the 134 treated patients, 90 were female (67.2%) and 24 male (17.9%). No information on sex was provided in the remaining 20 patients (14.9%). The patients were 8–78 years old (mean ± SD 45.1 ± 15.6) and had an average disease duration ranging from 0 to 30 (mean ± SD 5.8 ± 6.2) years.

Assessment of the disease duration and organ manifestations is presented in Table 2.

Disease duration: A variety of definitions of disease duration were used, with time since diagnosis and time since onset of RP or first non-Raynaud symptom attributable to SSc being the most frequent definitions. Sometimes, there was no indication of the definition of disease duration, and in one article, different information was given for individual patients. Mean disease duration for each paper is mentioned, if parameters for calculation were available or disease duration reported.

Skin: Presence of skin fibrosis was defined as clinical and/or histological evidence of increased skin thickening measured by different skin scores in clinical examination, assessment of physician or patient, plicometry, elastometry, and/or skin biopsy. Clinical examination included the mRSS (estimating skin thickness in 17 body areas by palpation), the University of California at Los Angeles (UCLA) skin score (measuring 10 body areas by clinical palpation), the plicometer skin test (using a plicometer to evaluate nine skin areas), and a skin score without any further information.33,62,63

Lung: Pulmonary manifestations were assessed mainly by PFTs (restrictive ventilation disorder, reduced compliance, reduced diffusion capacity of carbon monoxide (DLCO), VC, or FVC). For the purpose of this study, PFTs were considered reduced when showing FVC or DLCO less than 80% of predicted value if no other definition was provided. Several studies referred to reduced lung function without information on the lung function values. Other measures consisted of chest radiography or high-resolution computed tomography (HRCT) revealing changes referred to as interstitial fibrosis, interstitial changes, or as ground-glass opacities and/or indication of pulmonary involvement without further details. In one study, lung findings were assessed also by blood gas analysis and right heart catheter determining PAH.39
Table 1. List of the analysed publications with information on study type, control group, and applied drugs.

| Publication                      | Study type       | Control | CNI  | Co-treatmentsa |
|----------------------------------|------------------|---------|------|----------------|
| al-Mayouf et al.25               | Case report      | No      | CsA  |                |
| Amor and Dougados26              | Case series      | No      | CsA  |                |
| Ando et al.27                    | Case report      | No      | CsA  | PSL\textsuperscript{LD} [1/1] |
| Appelboom and Itzkowitch28       | Case report      | No      | CsA  | PSL\textsuperscript{HD} [1/1] |
| Basso et al.29                   | Case series      | No      | CsA  |                |
| Basso et al.30                   | Case report      | No      | CsA  |                |
| Casoli et al.31                  | Case report      | No      | CsA  |                |
| Chen et al.32                    | Case report      | No      | CsA  |                |
| Clements et al.33                | Historically controlled trial | Yes | CsA  |                |
| Constantopoulos et al.34         | Case report      | No      | CsA  | PSL\textsuperscript{HD} [1/1] |
| Davies and Dunn35                | Case report      | No      | CsA  |                |
| Denton et al.36                  | Case series      | No      | CsA  | PSL\textsuperscript{LD} [1/3] |
| Filaci et al.37                  | Randomized controlled trial | Yes\textsuperscript{b} | CsA  |                |
| Francès et al.38                 | Case series      | No      | CsA  |                |
| Gisslinger et al.39              | Case series      | No      | CsA  | PSL\textsuperscript{LD} [4/8] |
| Heickendorff et al.40            | Case series      | No      | CsA  |                |
| Hider et al.41                   | Case report      | No      | CsA  | AZA [1/1]      |
| Ippoliti et al.42                | Case series      | No      | CsA  |                |
| Ishida et al.43                  | Case report      | No      | CsA  |                |
| Knop and Bonsmann24              | Case series      | No      | CsA  |                |
| Konma et al.44                   | Retrospective study | No | Tac  | PSL\textsuperscript{HD} [11/11] |
| Mehregan and Su45                | Case report      | No      | CsA  | PSL\textsuperscript{HD} [1/1] |
| Merot et al.46                   | Case report      | No      | CsA  | PSL\textsuperscript{HD} [1/1] |
| Morton and Powell47              | Case series      | No      | CsA, Tac | PSL\textsuperscript{LD} [1/15] |
| Nunokawa et al.48                | Case report      | No      | Tac  | PSL\textsuperscript{HD} [1/1] |
| Patrick et al.49                 | Case series      | Yes\textsuperscript{c} | CsA  |                |
| Quartier et al.50                | Case series      | No      | CsA  | PSL\textsuperscript{HD}, MTX [4/4] |
| Roch et al.51                    | Case report      | No      | CsA  |                |
| Tooze et al.52                   | Case report      | No      | CsA  |                |
| Vayssairat et al.53              | Case series      | No      | CsA  |                |
| Wörle et al.54                   | Case series      | No      | CsA  |                |
| Yamasue et al.55                 | Case report      | No      | Tac  | PSL\textsuperscript{LD} [1/1] |

(Continued)
Co-treatments were frequently used and are listed if other immunosuppressive agents including corticosteroids \(\text{PSL}_{\text{HD}} = \text{high-dose prednisone}\ (>10\ \text{mg/d})\), \(\text{PSL}_{\text{LD}} = \text{low-dose prednisone}\ (\leq 10\ \text{mg/d})\) have been applied.

The control group received iloprost, the treatment group iloprost, and CsA.

Healthy control group, but only to compare sIL-2R levels.

Table 1. (Continued)

| Publication                  | Study type | Control | CNI  | Co-treatments$^a$ |
|------------------------------|------------|---------|------|-------------------|
| Yocum and Wilder$^{56}$      | Case report| No      | CsA  |                   |
| Zachariae and Zachariae$^{57}$| Case series| No      | CsA  |                   |
| Zachariae et al.$^{58}$      | Case series| No      | CsA  |                   |
| Zachariae et al.$^{59}$      | Case report| No      | CsA  | PSL$^{60}_{\text{HD}}$ (1/1) |
| Zentilin et al.$^{60}$       | Case report| No      | CsA  |                   |

$^a$Co-treatments were frequently used and are listed if other immunosuppressive agents including corticosteroids \(\text{PSL}_{\text{HD}} = \text{high-dose prednisone}\ (>10\ \text{mg/d})\), \(\text{PSL}_{\text{LD}} = \text{low-dose prednisone}\ (\leq 10\ \text{mg/d})\) have been applied.

$^b$The control group received iloprost, the treatment group iloprost, and CsA.

$^c$Healthy control group, but only to compare sIL-2R levels.

Figure 1. Literature review flow diagram.

RP: In one case report, RP was provoked by cold stimulation. In the remaining studies, there was no indication of whether a cold stimulation test had been performed.

Oesophagus: To detect oesophageal involvement, manometry or radiologic imaging with barium containing contrast medium sometimes combined with 24-h pH-metry was used. If there was no indication of the diagnostic method used, oesophageal involvement was reported as dysphagia, esophagitis, reflux, dysmotility, or dysfunction.

Heart: Cardiac involvement was measured using echocardiography, chest X-ray, and/or electrocardiography.

At the start of therapy, all patients suffered from skin fibrosis and 73 (54.4%) from pulmonary manifestations. Baseline information on renal manifestations was limited and available in only 58 patients (20 studies).

Twenty-eight papers (75.7%) provided information on previous treatments. Previous disease-modifying drugs are listed in the “Treatment regimens” section.
| Study | Pat (F/M) | Disease subtype | Mean SSc duration (Min–Max) | Organ involvement |
|-------|-----------|----------------|-----------------------------|------------------|
| al-Mayouf et al.25 | 1 (1/0) | O | 6 years | Skin [1], lung [0], RP [1], oesophagus [0], heart [0] |
| Amor and Dougados26 | 2 (2/0) | D | N/A | Skin [2], lung [2], RP [2], oesophagus [2], heart [-] |
| Ando et al.27 | 1 (1/0) | D | 0 years | Skin [1], lung [1], RP [-], oesophagus [-], heart [-] |
| Appelboom and Itzkowitch28 | 1 (1/0) | N/A | ~0.42 years | Skin [1], lung [1], RP [0], oesophagus [1], heart [1] |
| Basso et al.29 | 9 (7/2) | D § | 9.6 years [3–20 years] | Skin [9], lung [7], RP [-], oesophagus [8], heart [0] |
| Basso et al.30 | 1 (1/0) | N/A | 4 years | Skin [1], lung [1], RP [1], oesophagus [1], heart [-] |
| Casoli et al.31 | 1 (1/0) | N/A | 0.5 years | Skin [1], lung [1], RP [1], oesophagus [-], heart [-] |
| Chen et al.32 | 1 (0/1) | D | 0.5 years | Skin [1], lung [-], RP [1], oesophagus [-], heart [-] |
| Clements et al.33 | 10 (8/2) | D (9), L (1) § | ~1.9 years [<=5 years] | Skin [10], lung [7], RP [-], oesophagus [7], heart [4] |
| Constantopoulos et al.34 | 1 (1/0) | D | 9 years | Skin [1], lung [1], RP [0], oesophagus [-], heart [-] |
| Davies and Dunn35 | 1 (0/1) | D | 2 years | Skin [1], lung [0], RP [1], oesophagus [1], heart [0] |
| Denton et al.36 | 3 (3/0) | D | N/A [2–3 years] | Skin [3], lung [1], RP [2], oesophagus [1], heart [-] |
| Filacri et al.37 | 10 (N/A) | D (8), L (2) § | N/A (~2 years) | Skin [10], lung [-], RP [10], oesophagus [-], heart [-] |
| Francès et al.38 | 4 (N/A) | D § | N/A [<2.5 years] | Skin [4], lung [2], RP [-], oesophagus [4], heart [-] |
| Gisslinger et al.39 | 8 (4/4) | N/A § | 4.5 years [1–8 years] | Skin [8], lung [7], RP [-], oesophagus [8], heart [8] |
| Heickendorff et al.40 | 6 (N/A) | N/A § | N/A | Skin [6], lung [-], RP [-], oesophagus [-], heart [-] |
| Hider et al.41 | 1 (1/0) | L | 3 years | Skin [1], lung [1], RP [1], oesophagus [-], heart [0] |
| Ippoliti et al.42 | 5 (4/1) | N/A § | N/A | Skin [5], lung [4], RP [-], oesophagus [4], heart [1] |
| Ishida et al.43 | 1 (1/0) | D § | N/A | Skin [1], lung [1], RP [1], oesophagus [1], heart [-] |
| Knop and Bonsmann44 | 3 (2/1) | N/A § | N/A [>3 years] | Skin [3], lung [2], RP [3], oesophagus [-], heart [-] |
| Konma et al.45 | 11 (11/0) | D (7), L (4) | N/A | Skin [11], lung [11], RP [-], oesophagus [-], heart [-] |
| Mehregan and Su46 | 1 (1/0) | N/A | 2.5 years | Skin [1], lung [-], RP [1], oesophagus [-], heart [-] |
| Mérot et al.47 | 1 (0/1) | N/A | 0.75 years | Skin [1], lung [1], RP [-], oesophagus [-], heart [1] |
| Morton and Powell48 | 15 (12/3) | D (8), L (5), O (2) § | 7.9 years [<1–27 years] | Skin [15], lung [-], RP [11], oesophagus [10], heart [1] |
| Nunokawa et al.49 | 1 (1/0) | D | 5 years | Skin [1], lung [-], RP [1], oesophagus [1], heart [1] |
| Patrick et al.50 | 4 (2/2) | D (3), L (1) | 4.5 years [2–8 years] | Skin [4], lung [3], RP [-], oesophagus [4], heart [-] |
| Quartier et al.51 | 4 (4/0) | D § | ~0.69 years. (0.3 to ~1.2 years) | Skin [4], lung [3], RP [3], oesophagus [4], heart [4] |
| Roch et al.52 | 1 (1/0) | N/A | 1.75 years | Skin [1], lung [1], RP [1], oesophagus [1], heart [-] |
| Tooze et al.53 | 1 (0/1) | N/A | 0.5 years | Skin [1], lung [0], RP [0], oesophagus [0], heart [0] |
| Vayssairat et al.54 | 4 (3/1) | N/A | 4.5 years [2–7 years] | Skin [4], lung [3], RP [4], oesophagus [3], heart [0] |
| Wörle et al.55 | 4 (4/0) | D (2), L (2) § | 9.5 years [1–21 years] | Skin [4], lung [2], RP [4], oesophagus [4], heart [2] |
| Yamase et al.56 | 1 (1/0) | N/A § | 0 years | Skin [1], lung [1], RP [1], oesophagus [1], heart [-] |

(Continued)
Table 2. (Continued)

| Study                          | Pat (F/M) | Disease subtype | Mean SSC duration (Min–Max) | Organ involvement                      |
|-------------------------------|-----------|-----------------|-----------------------------|----------------------------------------|
| Yocum and Wilder56            | 1 (1/0)   | D               | 3.5 years                   | Skin (1), lung (1), RP (1), oesophagus (1), heart (0) |
| Zachariae and Zachariae57     | 2 (1/1)   | D [1], N/A [1]  | N/A [1 to several years]    | Skin (2), lung [-], RP (1), oesophagus (1), heart [-] |
| Zachariae et al.58            | 10 (7/3)  | D [3], L [7] §  | 11.4 years [1–30 years]     | Skin [10], lung [8], RP [-], oesophagus [9], heart [-] |
| Zachariae et al.59            | 1 (1/0)   | D               | 8 years                     | Skin (1), lung [0], RP [-], oesophagus (1), heart [-] |
| Zentlin et al.60              | 2 (2/0)   | N/A             | 2.75 years [0.5–5 years]    | Skin (2), lung [-], RP (2), oesophagus (2), heart [-] |

Pat, total patient number; F/M, number of females/number of males; N/A, information not available.
Subtypes: D (diffuse), L (limited), and O (overlap), numbers in parenthesis are the number of patients affected, §: patients fulfilling the ACR criteria. [-] = not examined/not specified; [0] = examined and organ manifestation excluded.

Several patients received medication for RP. However, there was no information provided neither on how many patients nor on the number of patients affected by RP.

Lung involvement as well as oesophageal and cardiac manifestations and their development during CsA therapy have been observed. However, there was no information on the number of patients affected before initiation of therapy.

**Treatment regimens**

In 34 of 37 papers, patients had CsA treatment. In most studies, dosage was given in mg/kg/d. CsA was applied in dosages between 1 and 10 mg/kg/day body weight (mean 4.4 mg/kg/day). However, the dose was adjusted in the majority of papers during treatment. In three cases, the only information given was in mg daily (range 150–300 mg) and/or as serum concentration.27,28,35 CsA was administered over a period of 13 days to more than 5 years, with a mean treatment duration of 15 months.

Twenty-one patients from four studies received Tac: 13 patients in three studies as first-line therapy between 1 and 8 mg daily (mean 2.6 mg/d) and eight patients in one study as second-line treatment.44,47,48,55 Treatment duration was between 21 days to 469 weeks (mean 22 months).

Twenty-two papers (59.4%) reported that other immunosuppressive drugs were concomitantly administered in addition to CNI therapy. CNIs were used as first-line therapy in only one study with two patients.38 Accordingly, prior application with other agents than CNIs were frequent. Previous potentially disease-modifying drugs included corticosteroids (27 patients), D-penicillamine (24 patients), azathioprine (AZA, 14 patients), methotrexate (MTX, 8 patients), hydroxychloroquine (5 patients), cyclophosphamide (4 patients), colchicine (3 patients), intravenous immune-globulins (3 patients), pentoxifylline (3 patients), and interferon (3 patients). Co-treatments were frequently used including corticosteroids and other immunosuppressive agents (aza; MTX, prednisone high/low dose (>10 mg/day/≤10 mg/day), iloprost) (Table 1).

**Effects on skin fibrosis**

Therapeutic effects on skin fibrosis over time were observed in 96 (89.7%) patients of 27 studies involving 107 patients, of which eight patients of five studies did receive co-treatments with potentially disease-modifying immunosuppressive drugs. Different methods were used to assess skin fibrosis (Tables 3 and 4).

An improvement of skin fibrosis was experienced by 77 of 96 (80.2%) patients, of which three patients were also taking high-dose PSL and four patients a combination therapy of high-dose PSL and MTX together with CNI. Improvement was described as ‘normalization’, ‘improvement’, or ‘slight improvement’. Endpoints used to assess effectiveness were global physician and patient assessment (33 patients), skin scoring (22 patients), plicometry (17 patients), and elastometry (five patients). Skin biopsies confirmed findings of clinical examinations in two studies (three patients). An unchanged and stable course of skin fibrosis was reported in 15 patients (15.6%) within six studies. Assessments were done by
### Table 3. Course of skin fibrosis under CNI therapy (without potential disease-modifying immunosuppressive co-treatments).

| Publication                        | Measuring method during process | Patients [number] | Improvement [number] | Unchanged [number] | Worsening [number] | Not provided [number] | Significant improvement |
|-----------------------------------|---------------------------------|-------------------|---------------------|-------------------|-------------------|----------------------|------------------------|
| Davies and Dunn                   | M                               | 1                 | 1                   | –                 | –                 | –                    | S                      |
| Gisslinger et al.                  | P                               | 9                 | 7                   | 2                 | 1                 | 1                    | S                      |
| Heickendorff et al.                | M                               | 1                 | 1                   | 6                 | –                 | –                    | S                      |
| Hider et al.                      | R                               | 10                | 1                   | 1                 | –                 | –                    | S                      |
| Ishida et al.                     | U                               | 1                 | 1                   | 1                 | –                 | –                    | S                      |
| Mehregan and Su                   | M                               | 3                 | 3                   | 2                 | –                 | –                    | S                      |
| Mérot et al.                      | SS                              | 10\(^a\)          | 1                   | 1                 | –                 | –                    | S                      |
| Morton and Powell                 | P                               | 4                 | 2                   | 2                 | –                 | –                    | S                      |
| Nunokawa et al.                   | M, B                            | 8                 | 7                   | 7                 | –                 | –                    | S                      |
| Patrick et al.                    | R                               | 5                 | 5                   | 5                 | –                 | –                    | S                      |
| Tooze et al.                      | E                               | –                 | –                   | –                 | –                 | –                    | S                      |

**Evaluation:** M, assessment of a physician; M+, assessment of physician and patient; R, RSS; U, UCLA skin score; SS, skin score without any further information; B, biopsy; P, plicometry skin score; E, elastometry.

Numbers in parenthesis are the number of patients affected.

\(^a\)Significant improvement of skin sclerosis in the patient group without information on individual disease course.

\(^b\)One patient showed improvement without any further information; another showed improvement in digital ulcers without specific information on skin fibrosis.
Table 4. Course of skin fibrosis under CNI therapy (with potential disease-modifying immunosuppressive co-treatments).

| Publication                        | Measuring method during process | Patients (number) | Improvement (number) | Unchanged (number) | Worsening (number) | Not provided (number) | Significant improvement |
|-----------------------------------|--------------------------------|------------------|----------------------|--------------------|--------------------|-----------------------|-------------------------|
| Appelboom and Itzkowitch28        | M+                             | 1                | 1                    | –                  | –                  | –                     | N                       |
| Constantopoulos et al.24          | M                              | 1                | 1                    | –                  | –                  | –                     | N                       |
| Méro et al.44                     | M                              | 1                | –                    | –                  | 1                  | –                     | N                       |
| Nunokawa et al.48                 | M                              | 1                | –                    | –                  | –                  | –                     | N                       |
| Quartier et al.50                 | SS                             | 4                | –                    | –                  | –                  | –                     | N                       |

Evaluation: M, assessment of a physician; M+, assessment of physician and patient; SS, skin score without any further information. Numbers in parenthesis are the number of patients affected. N, no information on significance available.

global physician/patient assessment (eight patients), skin scoring (five patients), and plicometry (two patients). Worsening of skin fibrosis was observed in four patients (4.2%) from four studies, one receiving concomitant therapy with high-dose PSL. Three patients deteriorated according to global physician assessment, and one of them reported worsening of mRSS.

In four patients of three studies, CsA was withdrawn after remission of skin fibrosis and the clinical course was reported after withdrawal.25,29,30 Three patients relapsed, one within 6 months, and CsA had to be re-started in all three patients.29,30 The fourth patient remained in remission.25

Because of the spontaneous regression of skin fibrosis often seen in patients with SSc, treatment studies without control groups must be interpreted with caution.24 We therefore report on the two studies with control groups in more detail. Both studies observed a significant improvement of skin fibrosis under CsA therapy. Clements et al.33 performed an open study with 10 patients under CsA treatment and compared the effects with a historical control group. The initial dose of 1 mg/kg/d CsA was increased to 5 mg/kg/d if tolerated. After 48 weeks of therapy, the UCLA skin score improved significantly versus baseline ($p < 0.0001$) and its improvement was significantly higher ($p < 0.004$) than in the historical control group. Six of the 10 patients had an improvement of skin score greater than 35%. In the randomized controlled study of Filaci et al.,37 the effects of CsA at a dose of 2.5 mg/kg/d versus no treatment were assessed in 20 patients. All patients received therapy with iloprost. After 12 months, the treatment group showed a significant decrease of the plicometry skin score ($p = 0.008$), while the score of the no-treatment control group decreased without significance ($p = 0.1$).

Effects on lung manifestations

Lung involvement at therapy start was reported in 29 studies. Out of 96 patients, 74 (77.0%) had SSc-associated lung manifestations. Pathological PFTs were reported in 59 (61.5%) patients. Of these patients, 10 had a forced vital capacity (FVC) below 80% and 4 below 70% predicted. Twenty-nine patients had ILD confirmed by chest radiography or HRCT. Twenty-three of these patients had both altered PFTs and interstitial changes on imaging.
PAH was diagnosed in six patients of two studies, one study with five patients using a right heart catheter for diagnosis, while for the sixth patient, the definition of PAH diagnosis was not provided. Finally, pulmonary involvement was mentioned in seven patients without further details.

We next assessed changes under treatment based on their outcome measures. For PFTs, the following changes were reported (Tables 5 and 6, n=22 studies). In 28 patients, the course of pathological PFTs have been described individually, improving in 19, remaining stable in eight and aggravating in one patient. Another patient did not have pulmonary

| Study                  | Ando et al.27 | Basso et al.29 | Basso et al.30 | Casoli et al.31 | Clements et al.33 | Davies and Dunn35 |
|------------------------|---------------|----------------|----------------|------------------|-------------------|------------------|
| Number Pat.            | 1             | 9              | 1              | 1                | 10                | 1                |
| Lung findings before therapy | 1 (L, H)      | 7 (L)          | 1 (L)          | 1 (L, T)         | 4 [T], 3 [K]      | 0 [T, L]         |
| Improvement            | 1 (L)         | 7 (L)          | 1 (L)          | 1 (L, T)         | –                 | –                |
| Unchanged              | 1 (H)         | 2              | –              | –                | 4 (T)             | –                |
| Deterioration          | –             | –              | –              | –                | 1, T, L           | –                |

| Study                  | Filaci et al.37 | Francès et al.38 | Gisslinger et al.39 | Ippoliti et al.40 | Ishida et al.41 | Roch et al.42 |
|------------------------|-----------------|-----------------|-------------------|------------------|----------------|--------------|
| Number Pat.            | 10              | 4              | 8                 | 5                | 1              | 1            |
| Lung findings before therapy | N.A.           | 2 (L)          | 4 [T], 5 [P]      | 4 [K]            | 1 [L]         | 1 [L]        |
| Improvement            | –               | –              | 5 (P)            | 4 [L]b           | 1 (L)         | 1 (L)        |
| Unchanged              | 10ns L          | 2 (L)          | 3 (T)            | –                | –              | –            |
| Deterioration          | –               | –              | 1 (Pn), 1 (T)    | –                | –              | –            |

| Study                  | Vayssairat et al.53 | Wörte et al.54 | Yamasue et al.55 | Yocum and Wilder56 | Zachariae and Zachariae57 |
|------------------------|----------------------|----------------|-----------------|-------------------|---------------------------|
| Number Pat.            | 4                    | 4              | 1               | 1                 | 2                         |
| Lung findings before therapy | 3 (L, T)          | 2 [Lc]         | 1 (L, H)        | 1 [L]             | N.A.                     |
| Improvement            | –                    | 1 (Lc)         | –               | –                 | 1d (L)                    |
| Unchanged              | 3 (L, T)            | 1 (L)          | –               | 1 (L)             | –                         |
| Deterioration          | –                    | –              | 1 (L, H)        | –                 | –                         |

*The line ‘lung findings’ shows the number of patients with pulmonary involvement and their corresponding pathology before CNI therapy. These patients are documented with highlighted (bold) writing. Narrow, italic numbers stand for the course of patients without lung manifestation before therapy (if documented).

L, pathological lung function (in spirometry or Dlco); T, pulmonary manifestation on chest radiography; H, pulmonary manifestation in HRCT; P, PAH; Pn, PAH developed under CsA therapy; K, indication of pulmonary involvement, but neither diagnosis nor explicit disease course was available.

Significant improvement of the mean lung function score after 3 years compared to the start of therapy (p = 0.03).

Non-significant change in the patient population and no information on the individual patient course.

Improvement of organ manifestations was reported without specific mention of pulmonary involvement.

Partial recovery of lung function in the patient population without further details.

An improvement in respiratory function has been reported in one patient with no indication of whether PFTs have been performed or not.

Improvement of FEV1 from 1.7 to 1.9 L in lung function without further details.
Table 6. Development of pulmonary manifestations under CNI therapy (with potential disease-modifying immunosuppressive co-treatments).

| Study                          | Appelboom and Itzkowitch²⁸ | Constantopoulos et al.³⁴ | Hider et al.⁴¹ | Konma et al.⁴⁴ | Quartier et al.⁵⁰ |
|-------------------------------|-----------------------------|---------------------------|----------------|----------------|------------------|
| Number Pat.                   | 1                           | 1                         | 1              | 11             | 4                |
| Lung Findings before therapy  | 1 (L)                       | 1 (L, T)                  | 1 (L, H)       | 10 (L), 11 (H) | 3 (L)            |
| Improvement                   | 1 (L)                       | 1 (L, T)                  | 1 (L)          | 3              | 2 (L)            |
| Unchanged                     | –                           | –                         | 1 (H)          | 7              | 1 (L)            |
| Deterioration                 | –                           | –                         | –              | 1              | –                |

The line ‘lung findings’ shows the number of patients with pulmonary involvement and their corresponding pathology before CNI therapy. These patients are documented with highlighted (bold) writing. Narrow, italic numbers stand for the course of patients without lung manifestation before therapy (if documented). L, pathological lung function (in spirometry or Dlco); T, pulmonary manifestation on chest radiography; H, pulmonary manifestation in HRCT.

*Therapy effectiveness of Tac was assessed according to the ATS/ERS guidelines using three criteria (decrease in symptoms, reduction of abnormalities on HRCT, and improved lung function). Treatment response was defined as ‘improved response’, ‘stable response’, or ‘failure to respond to therapy’ according to which of the criteria were met. It was not possible to draw conclusions about individual changes in the three criteria.

manifestations at the beginning but rather developed them during CsA therapy.³⁵ Of these patients, six had been receiving high-dose PSL alone or in combination with MTX concomitantly to CNI therapy. In the retrospective study including 11 patients with interstitial pneumonia treated with Tac and high-dose PSL, changes in PFTs were assessed in the whole patient group without information on the individual disease course.⁴⁴ After 1 year of Tac administration, pulmonary function did not significantly change on the group level.

Studies also reported changes on imaging outcomes: Of the 29 patients using X-ray or HRCT to evaluate interstitial changes, information on the individual lung changes over time was available in 16 cases (55.2%). Over the course of therapy, interstitial changes improved in two, remained stable in 12 and worsened in another two patients. The same patient who developed pathological lung function under therapy also developed new pulmonary fibrosis on chest X-ray.³⁶ The retrospective study reported a decrease in the total fibrosis score in HRCT after 1 year of Tac but without significance, while the total ground-glass opacity (GGO) score showed a significant decrease (p = 0.005).

Combined outcomes measures were also reported in some studies: A detailed evaluation of the lung findings in eight SSc patients was performed by Gisslinger et al.³⁹ The lung findings were assessed by blood gas analysis, chest X-ray, and PFTs at baseline and after 6 months of CsA therapy. Before therapy, seven of the eight patients showed pathological lung findings: Pulmonary hypertension (five patients), ILD on chest X-ray (four patients), hypoxemia (four patients), and a VC ⩽ 80% predicted (four patients). PAH improved in all five affected patients, but another patient newly developed PAH during CsA therapy. One of the five PAH patients died 9 months after starting therapy despite improvement in PAH. The autopsy showed fibrinous pericarditis. Four of the five patients with improved PAH under CsA therapy received interferon-2 as additional drug and two patients received 2 mg PSL daily. Interstitial fibrosis on chest X-ray worsened in one of the four patients, while it remained unchanged in the other three. Hypoxemia improved in all four patients. FVC normalized to >80% in two patients, while it remained <80% in the other two.

Adverse events during CNI therapy
Renal adverse events were reported in 58 patients (43.3%, Tables 7 and 8). Seven patients experienced severe renal complications: one with confirmed hemolytic uremic syndrome (HUS) after
### Table 7. Kidney function under CNI therapy (without potential disease-modifying immunosuppressive co-treatments).

| Study | Amor and Dougados\(^{26}\) | Casoli et al.\(^{21}\) | Chen et al.\(^{32}\) | Clements et al.\(^{33}\) | Denton et al.\(^{34}\) | Francés et al.\(^{38}\) | Gisslinger et al.\(^{39}\) | Heickendorff et al.\(^{40}\) |
|-------|-----------------------------|------------------------|----------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
| Patients | 2 | 1 | 1 | 10 | 3 | 4 | 8 | 6 |
| Patients with renal side effects\(^{3}\) | 2 | 1 | 1 | 8 | 3 | 1 | 4 | 6 |
| Severe complications | – | N1 | N2 | N3 [1] | – | N4 | – | – |
| Renal biopsy | M, F, I, A [1] | R | D | – | T [2] | – | – | sf [2] |
| Cr increase\(^{c}\) | 2 | 1 | 1 | 8 | 3 | N/A | 4 | 6 |
| Cr increase >30% | 2 | N/A | 1 | 8 | N/A | N/A | 4 | N/A |
| Highest Cr/ lowest Cr clearance \(^{1}\) | **517; 330 μmol/L** | **220; 350 μmol/L** | **~440; 840 μmol/L** | **70.4–238; 295 μmol/L** (mean 123.2) | 3\(^{*}\); 21; 28 mL/min\(^{*}\) | N/A | 124–150 μmol/L | N/A |
| Proteinuria | N/A | N/A | 1 | N/A | N/A | N/A | N/A | N/A |
| Haematuria | N/A | N/A | 1 | N/A | N/A | N/A | N/A | N/A |
| Hypertension | 2 | 1 | 1 | 2 | 3 | N/A | N/A | N/A |
| Highest blood pressure | 200/130; 190/120 | 190/120 | 170/100 | >140/90 | 240/130, N.A. [2] | N/A | N/A | N/A |

| Study | Knop and Bonsmanns\(^{24}\) | Ippoliti et al.\(^{42}\) | Ishida et al.\(^{43}\) | Morton and Powell\(^{47}\) | Vayssairat et al.\(^{51}\) | Wörle et al.\(^{54}\) | Zachariae et al.\(^{58}\) | Zentilin et al.\(^{60}\) |
|-------|-----------------------------|------------------------|----------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
| Patients | 3 | 5 | 1 | 15 | 4 | 4 | 10 | 2 |
| Patients with renal side effects\(^{3}\) | 1 | 5 | 1 | 2 | 1 | 3 | 3 | 2 |
| Severe complications | – | – | – | – | – | N6 [1] | – | – |
| Renal biopsy | – | – | – | – | – | – | AP [2] | – |
| Cr increase\(^{c}\) | 1 | **\(\beta\)** | 2 | 1 | 3 | 1 | 2 | 2 |
| Cr increase >30% | N/A | N/A | N/A | N/A | N/A | N/A | 1 | – |
| Highest Cr/ lowest Cr clearance | N/A | N/A | N/A | N/A | 135 μmol/L | 528\(^{3}\); ~132\(^{3}\); ~79\(^{5}\) μmol/L | N/A | N/A |
| Proteinuria | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Haematuria | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Hypertension | N/A | 2 | N/A | N/A | N/A | N/A | N/A | N/A |
| Highest blood pressure\(^{3}\) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |

Articles with reports on renal side effects are listed. Numbers in parenthesis are the number of patients affected.

- Numbers in parenthesis are the number of patients affected.
- \(-\), renal side effects did not occur; N/A, no information provided.

\(^{3}\)In numerous studies, no definition was provided on what was understood to be a renal complication. For the purpose of this study, all patients showing Cr increase above or Cr clearance below baseline during CNI treatment, pathological kidney biopsy consistent with SRC, SSC or CsA-arteriolopathy and b2-microglobulin as sign of renal damage were regarded to suffer from renal adverse events. In two articles, serum Cr was considered abnormal only with values below 1.2 mg/dL (105.6 μmol/L) or 125 μmol/L, respectively.\(^{32,39}\)

\(^{3}\)Increase of Cr or decrease of Cr clearance.

\(^{5}\)If the information on serum Cr was provided in mg/mL or mg/dL, it was converted into μmol/L (mg/dL = 88.4 μmol/L).

\(^{5}\)β, increase of urinary b2-microglobulin without any further information or adverse events.

\(^{3}\)Only one study defined hypertension as having a diastolic blood pressure over 90 mmHg, all the other articles dealing with patients having hypertension did not provide any definitions.\(^{39}\)

\(^{3}\)N1; SRC (sudden onset of renal failure and malignant hypertension) developed 16 days after CsA withdrawal and was histologically confirmed after death following haemorrhagic insult.

\(^{*}\)One patient had a severe loss of renal function after withdrawal from CsA.

\(^{*}\)A significant decrease of Cr clearance was shown without any further manifestations or complications.
Table 8. Kidney function under CNI therapy (with potential disease-modifying immunosuppressive co-treatments).

| Study                                                                 | Appelboom and Itzkowitch²⁸ | Konma et al.⁴⁴*** | Nunokawa et al.⁴⁸ | Zachariae et al.⁵⁹ |
|----------------------------------------------------------------------|-----------------------------|-------------------|-------------------|-------------------|
| Patients                                                             | 1                           | 11                | 1                 | 1                 |
| Patients with renal side effects                                        | 1                           | 11                | 1                 | 1                 |
| Severe complications                                                   | –                           | –                 | N⁵                | N⁷                |
| Renal biopsy                                                          | –                           | –                 | R                 | M                 |
| Cr increase              | 1                           | 1                 | 1                 | 1                 |
| Cr increase >30%                                                      | N/A                         | N/A               | N/A               | 1                 |
| Highest Cr²/lowest Cr clearance                                       | 29 mL/min                   | 45.8⁵–108.2⁵ µmol/L | 530⁵ µmol/L       | 201 µmol/L        |
| Proteinuria                                                          | N/A                         | N/A               | 1                 | 1                 |
| Haematuria                                                            | N/A                         | N/A               | 1                 | 1                 |
| Hypertension                                                          | –                           | N/A               | 1                 | 1                 |
| Highest blood pressure                                                | –                           | N/A               | 174/72            | 180/110           |

Articles with reports on renal side effects are listed. Numbers in parenthesis are the number of patients affected.

-renal side effects did not occur, N/A = no information provided.

In numerous studies, no definition was provided on what was understood to be a renal complication. For the purpose of this study, all patients showing Cr increase above or Cr clearance below baseline during CNI treatment, pathological kidney biopsy consistent with SRC, SSc or CsA-arteriolopathy and β₂-microglobulin as sign of renal damage were regarded to suffer from renal adverse events. In two articles, serum Cr was considered abnormal only with values below 1.2 mg/dL (105.6 µmol/L) or 125 µmol/L, respectively.³²,³⁹

CIncrease of Cr or decrease of Cr clearance.

If the information on serum Cr was provided in mg/mL or mg/dL, it was converted into µmol/L (mg/dL = 88.4 µmol/L).

bIncrease of urinary β₂-microglobulin without any further information or adverse events.

N¹: SRC (sudden onset of renal failure and malignant hypertension) developed 16 days after CsA withdrawal and was histologically confirmed after death following haemorrhagic insult.

***Renal side effects after one year of Tac administration.

combination therapy with CsA and high-dose PSL; one with HUS rather than renal crisis, but a differentiation was not clearly possible; one with SRC, developed 16 days after withdrawal from CsA and was confirmed histologically after death; two with renal crisis or CsA renal toxicity which could not be differentiated; one with SRC confirmed by corresponding renal biopsy; and finally one patient dying from renal insufficiency without the cause of renal insufficiency being identified.³¹–³³,³⁸,⁴⁸,⁵⁴,⁵⁹ The raised serum creatinine of these patients was measured between 200 and 530 µmol/L.

An increase of serum creatinine or a decrease in creatinine clearance without severe renal side effects was detected in 48 patients, in 31 of 48 patients, serum creatinine ranging from >125 to <300 µmol or creatinine clearance decreasing on values <30 mL/min, respectively.²⁶,²⁸,³³,³⁶,³⁹,⁴⁴,⁵³,⁵⁴ In 17 of the 48 patients, creatinine/creatinine clearance was not quantified. Another three patients with renal side effects had no information on creatinine/creatinine clearance reported. One of them had an increase of urinary β₂-microglobulin without any other diagnosis or information, while the other two showed pathologic renal biopsy with CsA-induced arteriolopathy, one of them having just a slightly changed histology.³³,⁵⁸

Altogether, hypertension was noticed in 13 patients.²⁶,³¹–³³,³⁶,⁴²,⁴⁸,⁵⁹ Pathological renal biopsy was reported in 11 patients.²⁶,³¹,³²,³⁶,⁴⁰,⁴⁸,⁵⁸,⁵⁹
Next, we assessed how often adverse events led to discontinuation of CNI therapy. In total, 39 of 134 (29.1%) patients showed considerable renal but also extra-renal adverse events, leading to reduction (five cases), interruption, or withdrawal (29 cases) from CNI therapy or death (five cases). Besides, severe kidney adverse events (7 cases), neurological adverse events (six cases), and insufficient therapy of CsA (six cases) were among the most frequent causes for discontinuation. In one patient, the immunosuppressive therapy led to exacerbation of autoimmune pulmonary alveolar proteinosis and development of adenocarcinoma of the lungs. Death occurred in five cases during CsA therapy or soon after withdrawal. Three patients died of cardiac adverse events (pericarditis, fibrosis, and heart insufficiency), one suffered from acute renal insufficiency and in one case no information on the cause of death was provided.

Discussion

Important results

This systematic literature review contains the findings of 37 articles, two of them being controlled studies: one with a prospective randomized no-treatment control group and another with a retrospective historical control group. Overall, 134 SSc patients treated with CNIs were identified from all studies, most of them suffering from dcSSc, which is the classical indication to apply potentially disease-modifying agents.

The most frequently used CNI was CsA with doses varying between 1 and 10 mg/kg body weight (mean 4.4 mg/kg) or 150–300 mg/d, respectively. Tac was applied between 0.03 and 0.18 mg/kg daily (mean 0.04 mg/kg) or 1–8 mg daily (mean 2.6 mg/d). These wide dose ranges indicate the lack of consensus regarding CNI therapy and its optimal treatment dosage. Limited data are available for the treatment of SSc with Tac because it has only been used in four of the 37 papers.

In most of the papers, CNIs were used as a second-line therapy. Out of the 28 papers (75.7%) providing information about previously used agents, only two patients from one study reported receiving CNIs as a first-line treatment. This implies that many patients already had ineffective previous therapies, suggesting severe and treatment-resistant forms of SSc, which needs to be taken into account when interpreting treatment effectiveness for CNIs. Furthermore, as most patients identified in this systematic literature review suffered from the dcSSc (53%) which is a known risk factor for SRC, the prevalence of renal insufficiency and kidney-related adverse events have to be interpreted with caution. The combination of potentially nephrotoxic CNIs in patients at risk for renal complications might not be representative for the overall SSc population. Another important point to consider when interpreting the result is the long disease duration with a mean of 5.8 years (range 0–30 years). In these later stages of SSc, the disease course is getting less dynamic, and treatment effects are more difficult to show because of the overall more stable natural course.

Therapy results

Given the limitations mentioned above and the general limitations of interpreting effectiveness from literature reviews, this study provides signals for potential effectiveness of CNIs to treat skin fibrosis in SSc patients. Most patients (80.2%) had an improvement of fibrosis, among them the patients in both studies with control groups, showing a significant reduction of skin fibrosis under CsA therapy. Unfortunately, the quality of the control groups was limited consisting of a historical control group and a no-treatment control group, respectively. A parallel placebo or effective treatment control group would be required to reach a higher level of evidence, particularly in SSc, where spontaneous regression of skin fibrosis under a standard of care is frequent. However, potential effectiveness of CNIs is further underlined by the finding that 18 articles showed a clinically important improvement of skin fibrosis.

CNIs could also have a positive effect on pulmonary fibrosis. Pulmonary function improved in almost 70% of the patients (19/28) who were individually assessed during the studies. In contrast to PFTs, imaging showed no improvement in most patients (14/16) during CNI therapy. This might not be surprising considering the low sensitivity to change of qualitative assessment of imaging and X-rays specifically. Indeed, HRCT was performed in four case reports only. The remaining studies used chest X-rays for diagnosis and evaluation of the course of pulmonary fibrosis. To better assess the effect on pulmonary fibrosis, a longitudinal, prospective, randomized, controlled study with sufficient treatment duration should be conducted.

PH, which was present in six patients at baseline, was assessed in five patients at follow-up,
reporting improvement in all patients. Another patient developed a new PAH under CsA therapy. However, due to these limited numbers, results from an open pilot study, the lack of a control group and the old definitions used for PAH at the time of the study, it is impossible to draw any conclusions on effectiveness for this indication. In addition, immunosuppressive drugs in general have not been confirmed to be an effective treatment strategy in patients with SSc-PAH.

Adverse events and complications
Severe renal side effects were reported in almost 10% of the patients included in this review, which is beyond what would be expected for such a population. Also considering the established nephrotoxicity of CNIs, therapy with CNIs should be conservatively selected and preferentially used in patients without risk factors for renal involvement. Renal toxicity of CsA has been shown to be dose-dependent. Therefore, high doses should be avoided until more robust RCT data with adequate control groups are available for effectiveness and (renal) toxicity. This statement is further supported by our data. Clements et al. reported that renal adverse events during therapy of SSc with CsA occur frequently with doses >3–4 mg/kg/day. Patients with severe renal adverse events had a dose range of CsA from 2.2 to 10 mg/kg, only 1 of 7 having a maximal dose lower than 3 mg/kg CsA per day.

Therapy withdrawal (29 cases), treatment interruption (five cases), or death (five cases) following side effects were frequent (31.7%). The main reasons were neurological (six patients) or renal manifestations (thirteen patients), which in one patient even ended fatally due to acute renal insufficiency. Despite good blood monitoring of CsA and early detection of nephrotoxicity, renal crisis occurred in three cases.

Interestingly, in an attempt to reduce side effects, a second-generation CNI, voclosporin, has been introduced more recently. Voclosporin has a higher potency than CsA requiring a 10 times lower dosage than CsA. It appears to be better tolerable and less nephrotoxic. This has been confirmed in phase II and phase III RCTs for chronic plaque psoriasis. However, while there was no increase in Cr levels at low-dose voclosporin (0.5 mg/kg/d), a significant increase of serum Cr was shown in the patient group treated with voclosporin 1.5 mg/kg/d compared to the placebo group, but the Cr values remained within normal range. A phase III, study reported on a slight reduction of GFR in eight out of 451 patients with plaque psoriasis, but no clinically significant renal toxicity. Whether these findings with lower toxicity are also holding true for a patient population with pre-existing risk for renal impairment like SSc, needs to be analysed in appropriate trials.

Strengths and limitations of this review
This review was performed systematically with predefined selection criteria. Consequently, this publication is the largest review about the treatment and side effects of CNIs in SSc patients. The most important limitation of this review is the heterogeneity of the available data. Numerous different outcome measures, inclusion criteria, and classification criteria were used. In addition, a variety of treatment regimens and dosages were applied, and most papers used retrospective, uncontrolled settings with small numbers of patients, making reliable conclusions on effectiveness and toxicity challenging.

Conclusion
In conclusion, this systematic literature review provides signals for a potential effectiveness of CNIs and particularly CsA for the treatment of skin and pulmonary fibrosis in SSc. However, the evidence level of the identified studies was low and the number of patients treated in the various studies was small, making reliable conclusions on effectiveness challenging. This shows the importance to conduct a larger, prospective randomized, double-blinded controlled trial to assess the effectiveness of CNIs on SSc patients.

The general dose-dependent nephrotoxicity of CNIs, which was confirmed in this study, has to be considered when designing such RCTs. This could be addressed by excluding patients at risk for SSc-associated renal manifestations from these trials and by closely monitoring renal toxicity in the trial. In addition, due to its reduced toxicity compared to CsA, voclosporin could be a promising candidate to be used in such RCTs.

Author contribution(s)
Nina N. Hofmann: Data curation; Formal analysis; Investigation; Visualization; Writing – original draft; Writing – review & editing.
Robert A. Ambühl: Data curation; Formal analysis; Investigation; Visualization; Writing – original draft; Writing – review & editing.

Suzana Jordan: Conceptualization; Methodology; Project administration; Supervision; Validation; Visualization; Writing – original draft; Writing – review & editing.

Oliver Distler: Conceptualization; Funding acquisition; Methodology; Supervision; Validation; Visualization; Writing – original draft; Writing – review & editing.

ORCID iD
Suzana Jordan https://orcid.org/0000-0002-8114-8239

Acknowledgements
The authors thank Mrs. Georgina Mathis for careful and detailed reading and editing the manuscript.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of interest statement
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: O. Distler has received consultancies, honoraria, speakers bureau, and/or grants/research support from the following companies in the area of potential treatments for systemic sclerosis and its complications in the last 3 years: Abbvie, Acceleron, Alcimed, Amgen, AnaMar, Arxx, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, ChemomAb, Corbus, CSL Behring, Galapagos, Glenmark, GSK, Horizon (Curzlon), Inventiva, iQvia, Kymera, Lupin, Medac, Medscape, Miltenyi, Mitsubishi Tanabe, Novartis, Roche, Roivant, Sanofi, Serodapharm, Topadur, and UCB. Patent issued ‘mir-29 for the treatment of systemic sclerosis’ (US8247389, EP2331143). The other co-authors have declared no competing interests.

Data availability
The protocol for the review was prepared and registered on the INPLASY portal (INPLASY2021100095; DOI: 10.37766/inplasy2021.10.0095). Template, data collection forms, data extracted from included studies, data used for all analyses, analytic code, and any other materials used in the review are available upon request from the authors. Part of the study will be used as master thesis (NNH) and doctoral thesis (RAA) at the University of Zurich.

Supplemental material
Supplemental material for this article is available online.

References
1. Denton CP and Khanna D. Systemic sclerosis. Lancet 2017; 390: 1685–1699.
2. Matucci-Cerinic M, Allonore Y, Czirják L, et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis 2009; 68: 1377–1380.
3. Distler O and Gay S. [Scleroderma]. Internist (Beri) 2010; 51: 30–38.
4. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013; 72: 1747–1755.
5. Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000; 43: 2445–2454.
6. Steen VD and Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001; 44: 2828–2835.
7. Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66: 754–763.
8. Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017; 76: 1897–1905.
9. Traub YM, Shapiro AP, Rodnan GP, et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore) 1983; 62: 335–352.
10. Mouton L, Bérezné A, Bussone G, et al. Scleroderma renal crisis: a rare but severe complication of systemic sclerosis. Clin Rev Allergy Immunol 2011; 40: 84–91.
11. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 2003; 29: 315–333.
12. Nihtyanova SI, Ong VH and Denton CP. Current management strategies for systemic sclerosis. *Clin Exp Rheumatol* 2014; 32: 156–164.

13. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. *Ann Rheum Dis* 2017; 76: 1327–1339.

14. Hoffmann-Vold A-M, Maher TM, Philpot EE, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. *Lancet Rheumatol* 2020; 2: e71–e83.

15. Schinke S and Riemekasten G. [Systemic sclerosis]. *Internist (Berl)* 2019; 60: 1251–1269.

16. Fuschiotti P. Current perspectives on the immunopathogenesis of systemic sclerosis. *Immunotargets Ther* 2016; 5: 21–35.

17. Walker UA, Saketkoo LA and Distler O. Haematopoietic stem cell transplantation in systemic sclerosis. *RMD Open* 2018; 4: e000533.

18. Kurz A. *European Commission approves nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)*. Boehringer Ingelheim, 2020, https://www.boehringer-ingelheim.com/press-release/europeancommissionapprovesnintedanibssc-ild

19. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. *N Engl J Med* 2019; 380: 2518–2528.

20. Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med* 2020; 8: 963–974.

21. Tiong BK, Hahn BH and Aung T. Treatment of autoimmune disease: established therapies. In: Rose NR and Mackay IR (eds) *The autoimmune diseases*. San Diego, CA: Elsevier, 2020, pp. 1209–1220.

22. Hunzelmann N, Moinzadeh P, Genth E, et al. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. *Arthritis Res Ther* 2009; 11: R30.

23. Sakkas LI and Platsoucas CD. Is systemic sclerosis an antigen-driven T cell disease. *Arthritis Rheum* 2004; 50: 1721–1733.

24. Knop J and Bonnmann G. Ciclosporin in the treatment of progressive systemic sclerosis. In: Schindler R (ed.) *Ciclosporin in autoimmune diseases*. Berlin, Heidelberg: Springer, 1983, pp. 199–200.

25. al-Mayouf SM, Silverman ED, Feldman BM, et al. Cyclosporine in the treatment of an unusual case of juvenile systemic sclerosis. *J Rheumatol* 1998; 25: 791–793.

26. Amor B and Dougados M. Ciclosporine: therapeutic effects in rheumatic diseases. *Transplant Proc* 1988; 20(3 Suppl. 4): 218–223.

27. Ando K, Nakashita T, Kaneko N, et al. Long-term efficacy and safety of maintenance therapy with azathioprine or ciclosporine for interstitial lung disease with diffuse cutaneous scleroderma. *Clin Exp Rheumatol* 2013; 31(2 Suppl. 76): 191–192.

28. Appelboom T and Itzkowitz D. Ciclosporin in successful control of rapidly progressive scleroderma. *Am J Med* 1987; 82: 866–867.

29. Basso M, Filaci G, Cutolo M, et al. Long-term treatment of patients affected by systemic sclerosis with ciclosporin A. *Ann Ital Med Int* 2001; 16: 233–239.

30. Basso M, Ghio M, Filaci G, et al. A case of successful pregnancy in a woman with systemic sclerosis treated with ciclosporin. *Rheumatology (Oxford)* 2004; 43: 1310–1311.

31. Casoli P, Carretti C and Tumiati B. Scleroderma renal crisis as a possible complication of ciclosporin A withdrawal. *Clin Rheumatol* 1994; 13: 126–128.

32. Chen WS, Young AH, Wang HP, et al. Hemolytic uremic syndrome with ischemic glomerulonephropathy and oblitative vasculopathy in a systemic sclerosis patient treated with ciclosporine-A. *Rheumatol Int* 2009; 29: 821–824.

33. Clements PJ, Lachenbruch PA, Sterz M, et al. Ciclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. *Arthritis Rheum* 1993; 36: 75–83.

34. Constantopoulos A, Dracou C and Tsoumakas C. Ciclosporin A in progressive systemic sclerosis. *Acta Paediatr* 1995; 84: 604.

35. Davies JM and Dunn HG. Interstitial lung disease developing during treatment with ciclosporine in a patient with diffuse scleroderma, aplastic anemia and Crohn’s disease: implications for pathogenesis and treatment. *J Clin Rheumatol* 1995; 1: 287–291.

36. Denton CP, Sweny P, Abdulla A, et al. Acute renal failure occurring in scleroderma treated with ciclosporin A: a report of three cases. *Br J Rheumatol* 1994; 33: 90–92.

37. Filaci G, Cutolo M, Scudeletti M, et al. Ciclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum
changes after 12 months of therapy. *Rheumatology* (Oxford) 1999; 38: 992–996.

38. Francès C, Branchet MC, Blétry O, et al. Skin collagen from scleroderma patients before and after cyclosporin A treatment. *Clin Exp Dermatol* 1988; 13: 1–3.

39. Gisslinger H, Burghuber OC, Stacher G, et al. Efficacy of cyclosporin A in systemic sclerosis. *Clin Exp Rheumatol* 1991; 9: 383–390.

40. Heickendorff L, Parvez A, Bjerring P, et al. Serum aminoterminal propeptide of type III procollagen in systemic sclerosis. A follow-up – investigations in subclasses and during therapy. *Acta Derm Venereol* 1991; 71: 185–188.

41. Hider SL, Woodhead M, Taylor PM, et al. Lung fibrosis in systemic sclerosis treated with a combination of ciclosporin and azathioprine. *Clin Exp Rheumatol* 2006; 24: 215.

42. Ippoliti G, Miori L, Negri M, et al. Cyclosporine in treatment of progressive systemic sclerosis: clinical and immunologic findings. *Transplant Proc* 1994; 26: 3117–3118.

43. Ishida K, Kamata T, Tsukagoshi H, et al. Progressive systemic sclerosis with CNS vasculitis and cyclosporin A therapy. *J Neurol Neurosurg Psychiatry* 1993; 56: 720.

44. Konma J, Kotani T, Shoda T, et al. Efficacy and safety of combination therapy with prednisolone and oral tacrolimus for progressive interstitial pneumonia with systemic sclerosis: a retrospective study. *Mod Rheumatol* 2018; 28: 1009–1015.

45. Mehrdad DR and Su WP. Cyclosporine treatment for dermatomyositis/polymyositis. *Cutis* 1993; 51: 59–61.

46. Mérat Y, Miescher PA, Balsiger F, et al. Cutaneous malignant melanomas occurring under cyclosporin A therapy: a report of two cases. *Br J Dermatol* 1990; 123: 237–239.

47. Morton SJ and Powell RJ. Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. *Rheumatology* (Oxford) 2000; 39: 865–869.

48. Nunokawa T, Akazawa M, Yokogawa N, et al. Late-onset scleroderma renal crisis induced by tacrolimus and prednisolone: a case report. *Am J Ther* 2014; 21: e130–e133.

49. Patrick MR, Kirkham BW, Graham M, et al. Circulating interleukin 1 beta and soluble interleukin 2 receptor: evaluation as markers of disease activity in scleroderma. *J Rheumatol* 1995; 22: 654–658.

50. Quartie P, Bonnet D, Fournet JC, et al. Severe cardiac involvement in children with systemic sclerosis and myositis. *J Rheumatol* 2002; 29: 1767–1773.

51. Roch B, Wollina U and Schroeder HE. Long-term cyclosporin A in systemic sclerosis. *J Eur Acad Dermatol Venereol* 2004; 18: 235–236.

52. Tooze JA, Marsh JC, Wickham N, et al. Response of aplastic anaemia and scleroderma to cyclosporin. *Br J Haematol* 1993; 85: 829–831.

53. Vayssairat M, Baudot N, Boitard C, et al. Cyclosporine therapy for severe systemic sclerosis associated with the anti-Scl-70 autoantibody. *J Am Acad Dermatol* 1990; 22: 695–696.

54. Wörle B, Hein R, Krieg T, et al. Cyclosporin in localized and systemic scleroderma – a clinical study. *Dermatologica* 1990; 181: 215–220.

55. Yamasue M, Nureki SI, Usagawa Y, et al. Elevated serum anti-GM-CSF antibodies before the onset of autoimmune pulmonary alveolar proteinosis in a patient with sarcoidosis and systemic sclerosis. *Tohoku J Exp Med* 2017; 243: 77–83.

56. Yocum DE and Wilder RL. Cyclosporin A in progressive systemic sclerosis. *Am J Med* 1989; 83: 369–370.

57. Zachariae H and Zachariae E. Cyclosporin A in systemic sclerosis. *Br J Dermatol* 1987; 116: 741–742.

58. Zachariae H, Halkier-Sørensen L, Heickendorff L, et al. Cyclosporin A treatment of systemic sclerosis. *Br J Dermatol* 1990; 122: 677–681.

59. Zachariae H, Hansen HE and Olsen TS. Hemolytic uremic syndrome in a patient with systemic sclerosis treated with cyclosporin A. *Acta Derm Venereol* 1992; 72: 307–309.

60. Zentilin P, Savarino V, Puppo F, et al. Improvement in esophageal motor abnormalities in systemic sclerosis patients treated with cyclosporine: comment on the article by Clements et al. *Arthritis Rheum* 1994; 37: 301–302.

61. Furst DE, Clements PJ, Hillis S, et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. *Arthritis Rheum* 1989; 32: 584–593.

62. Khanna D, Furst DE, Clements PJ, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. *J Scleroderma Relat Disord* 2017; 2: 11–18.

63. Nives Parodi M, Castagneto C, Filaci G, et al. Plicometer skin test: a new technique for the evaluation of cutaneous involvement in systemic sclerosis. *Br J Rheumatol* 1997; 36: 244–250.
64. Black C, Dieppe P, Huskisson T, et al. Regressive systemic sclerosis. *Ann Rheum Dis* 1986; 45: 384–388.

65. Fahr A. Cyclosporin clinical pharmacokinetics. *Clin Pharmacokin* 1993; 24: 472–495.

66. Li Y, Palmisano M, Sun D, et al. Pharmacokinetic disposition difference between cyclosporine and voclosporin drives their distinct efficacy and safety profiles in clinical studies. *Clin Pharmacol* 2020; 12: 83–96.

67. Bissonnette R, Papp K, Poulin Y, et al. A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. *J Am Acad Dermatol* 2006; 54: 472–478.

68. Papp K, Bissonnette R, Rosoph L, et al. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. *Lancet* 2008; 371: 1337–1342.